Fig. 4.
Utilisation of SMN-Augmenting therapies among alive individuals with SMA by A. Age deciles and B. SMA type∗. ∗Presymptomatic (n = 7) and SMA type 4 (n = 2) not included.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.